Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 126 points (-0.8%) at 15,723 as of Friday, Jan. 31, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,087 issues advancing vs. 1,837 declining with 186 unchanged. The Health Services industry currently sits down 0.7% versus the S&P 500, which is down 0.5%. On the negative front, top decliners within the industry include Hanger ( HGR), down 14.3%, C.R. Bard ( BCR), down 2.5%, Intuitive Surgical ( ISRG), down 1.6%, CareFusion ( CFN), down 1.5% and Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.5%. A company within the industry that increased today was HCA Holdings ( HCA), up 1.2%. TheStreet would like to highlight 5 stocks pushing the industry lower today: 5. Boston Scientific ( BSX) is one of the companies pushing the Health Services industry lower today. As of noon trading, Boston Scientific is down $0.11 (-0.8%) to $13.45 on light volume. Thus far, 3.7 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 10.9 million shares. The stock has ranged in price between $13.30-$13.47 after having opened the day at $13.40 as compared to the previous trading day's close of $13.56. Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $17.6 billion and is part of the health care sector. Shares are up 9.7% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 13 rate it a hold. TheStreet Ratings rates Boston Scientific as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and compelling growth in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full Boston Scientific Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.